This post is by Elly Vintiadis who recently guest-edited a special issue of Philosophical Psychology on psychedelic-assisted therapy and wrote a free access introduction to the special issue entitled The Promises and Perils of the Psychedlic Turn in Psychiatry . Elly Vintiadis Psychedelic substances have been part of human culture for centuries, used in ritual, healing and spiritual contexts to induce altered states of consciousness that could bring insight and change. In recent years, they have re-emerged in psychiatry in psychedelic-assisted therapy (PAT), a therapeutic framework in which substances such as psilocybin, LSD, MDMA, ketamine, or ibogaine are administered in controlled conditions, accompanied by preparation, supervision and integration. Research into psychedelic therapies flourished in the mid-20th century but came to a halt in the early 1970s, driven by shifting social attitudes and the onset of the War on Drugs. With their classification as Schedule I substances under ...
A blog at the intersection of philosophy, psychology, and mental health